Our science

Throughout 13 years of Selvita operations, we’ve had the opportunity to execute a variety of exciting and complex projects for our Clients.
The nature of our business is based on high degree of trust and confidentiality, however we are always very excited to co-author or contribute to scientific publications which present our work.

Whenever possible we publish and present materials such as journal publications, posters, case studies or technical notes, aiming to show the scope of experience of our scientific team.
In the section below, you can find the continuously updated information on our recent publications.

Our science

Blog

Go to blog

Case studies

More case studies

Webinars

Search by keyword
Drug Discovery
    Ardigen webinar – “AI methods in small molecule design.”

    Ardigen, a part of Selvita Group, will organize a live webinar “AI methods in small molecule design”. The event will take place on Tuesday, June 15, 2021, at 04:00 PM CEST and will be held by experts from three companies from Selvita Group - Ardigen (Dr. Michał Warchoł and Dr. Krzysztof Rataj), Selvita (Dr. Tom Coulter), and Fidelta (Dr. Steve Price).

    They will present and discuss various methods of AI application in drug design: the current state-of-the-art AI models for small molecules, which protein properties can be predicted and how to generate new molecules for your project.

    More information and registration at: https://ardigen.clickmeeting.com/ai-methods-in-small-molecule-design-/register

    Duration 1 hour Starting on the 16:06, 15 June 2021
    Fidelta Webinar - Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)
    Anamarija Markota, PhD
    Anamarija Markota, PhD Team Leader In Vivo Pharmacology
    Download presentation

      The download link has been sent to the e-mail address.

      Systemic lupus erythematosus (SLE) is a chronic and relapsing, autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. Mouse models of lupus are not only an indispensable tool for studying lupus immunopathogenesis but also serve as a powerful system for fast screening of new SLE treatments in order to evaluate their safety and efficacy prior to clinical trials. Due to the extensive heterogenicity of clinical manifestations of SLE in humans, each mouse model displays only specific attributes of the human lupus phenotype. The upcoming webinar will give an insight into the most commonly used mouse models of SLE, highlighting their similarities and differences and discussing the advantages of using one model over the other and tailoring it for specific needs in preclinical research in the context of our current understanding of the immunopathogenesis of SLE.

      Duration 1:00 Starting on the 15:06, 10 June 2021
      Regulatory Services
        Analytical outlook for biosimilar development
        Magdalena Bielak-Łakomska
        Magdalena Bielak-Łakomska Associate Director in Analytics
        Jan Smagur
        Jan Smagur Director of Cell and Molecular Biology Laboratory
        Krzysztof Stawujak
        Krzysztof Stawujak Business Development Manager
        View webinar

          The link has been sent to the e-mail address.
          Download presentation

            The download link has been sent to the e-mail address.

            The variability and complexity of biological medicines compel extensive and comprehensive characterization studies to ensure safety and efficacy. Compared to small-molecule drugs, structural and functional characterization of biologics can be a tedious and challenging process. It involves using state-of-the-art technologies to evaluate the purity, specificity, potency, and toxicity, all in accordance with international regulatory guidelines. During the webinar, Selvita’s Experts intend to characterize regulatory requirements and provide an outlook for analytical approaches for biosimilar development and manufacturing process changes.

            The webinar will feature a discussion between some of Selvita’s most experienced scientific team members: Magdalena Bielak-Łakomska, Associate Director in Analytics, and Jan Smagur, Director of Cell and Molecular Biology Laboratory, moderated by Krzysztof Stawujak, Business Development Manager.

            Duration 1:00 Starting on 15:04, 29 April 2021
            Drug Discovery
              A discussion on modern small molecule drug discovery
              Tom Coulter, PhD
              Tom Coulter, PhD Integrated Drug Discovery Director
              Przemyslaw Zawadzki, PhD
              Przemyslaw Zawadzki, PhD Director of Medicinal Chemistry
              Piotr Graczyk, PhD
              Piotr Graczyk, PhD Scientific Director
              Anna Karawajczyk, PhD
              Anna Karawajczyk, PhD Head of Computational Chemistry
              View webinar

                The link has been sent to the e-mail address.

                This webinar will feature a discussion between some of Selvita’s most experienced scientific team members, on selecting small molecule modalities to address protein targets in drug discovery. The debate will highlight areas of experience and recommendations for planning approaches for new projects. Dr. Anna Karawajczyk, Head of Computational Chemistry, will moderate a discussion of Dr. Tom Coulter, Integrated Drug Discovery Director, Dr. Przemyslaw Zawadzki, Director of Medicinal Chemistry and Dr. Piotr Graczyk, Scientific Director.

                Duration 1 hour Date 16:02, 03 February 2021

                Presentations

                Go to presentations

                Poster presentations

                Poster icon
                LC/HRMS ORBITRAP Technique - Essential tool in drug development process
                Download presentation

                  The download link has been sent to the e-mail address.
                  Poster icon
                  Cloning and Expression Platform for Production of Recombinant Proteins
                  The poster describes the cost and time-effective Selvita platform for cloning and E. coli expression (which is only one of our platforms for expression).
                  Download presentation

                    The download link has been sent to the e-mail address.
                    Poster icon
                    A short synthesis of Dronedarone
                    Selvita’s chemists are adept at designing enhanced approaches to target molecules and in this poster and paper illustrate how they collaborated on a synthesis of the atrial fibrillation drug Dronedrone which has been reworked to more than half the number of synthetic steps using efficient and environmentally friendly chemistry.
                    Download presentation

                      The download link has been sent to the e-mail address.
                      Go to poster presentations

                      Publications

                      Poster icon
                      Mitogenic activity and proliferative effect of a New-developed short acting Insulin analogue Human insulin analogues with modified amino acid sequence may exert stronger proliferative effect and carcinogenic potential than insulin itself. The objective of the study was to assess mitogenic activity and activation of proliferation in tumorigenic and non-tumorigenic cell lines upon stimulation with a new-developed short-acting B28Lys-B29Pro human insulin (KP) in comparison to EU Pharmacopeia human insulin standard (HIS) and insulin AspB10 with strong mitogenic, cancerogenic activity. Find out more
                      Go to publications

                      Technical notes

                      Development of an in vitro assay of neurodegeneration using human pluripotent stem cell–derived neurons

                      Human induced pluripotent stem cells (hiPSC) are obtained by genetically reprogramming somatic cells from human tissues, after which these cells can be further differentiated virtually into any cell types. hiPSC are derived from normal adults or from diseased patients and carry protein mutations that are able to compromise the cell physiology.

                      As consequence, hiPSC-derived cells reveal a high potential for studying pathophysiological processes in basically all pathological areas including CNS, PNS, peripheral tissues (cardiac, hepatic, pulmonary, muscular, vessel, blood, etc.)…

                      Find out more
                      Go to technical notes

                      Contact form

                        According to the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation; "GDPR"), we hereby inform you that Your personal data will be processed by Selvita S.A. and the companies operating within the Selvita Capital Group in order to present You the Selvita Newsletter. Your personal data are processed in connection with Newsletter subscription and in order to keep You informed about all events taking place in Selvita Capital Group.

                        We guarantee full transparency of the data processing and compliance with all the rights referred to in GDPR, i.e. the right of access, rectification and deletion of data, limiting data processing, the right to transfer, the right to raise objection against processing. Notwithstanding the above, You have the right to submit a complaint to the supervisory authority. Your personal data are not being subject to automated decision-making, including profiling. Your personal data are provided on the voluntary basis, however please be informed that lack of consent results in inability to provide You the Newsletter by Selvita Group. Your data will be processed for the duration of your consent, unless your consent to the processing of your personal data is revoked. Your consent may be withdrawn at any time by sending a request to the e-mail address: gdpr@selvita.com.

                        For more information on how Selvita handles personal data please visit: Privacy Policy. I hereby express my consent to the processing of my personal data by Selvita S.A. with registered office in Cracow 30-348, Bobrzyńskiego 14 and its affiliated companies in order to receive the Newsletter, information about events organized by the Selvita Capital Group and other information regarding Selvita Group activity in accordance with the Regulation 2016/679 of the European Parliament and the Council (EU) of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).